Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD

• The FDA designates privately-held Catabasis Pharmaceuticals' investigational NF-kB inhibitor, CAT-1004, an Orphan Drug for the treatment of Duchenne muscular dystrophy (DMD).
• NF-kB is a key mediator of cellular injury. Evidence suggests that activated NF-kB  contributes to the underlying pathology of DMD.
• In a Phase 1 trial, CAT-1004 was well-tolerated and demonstrated a significant reduction of activated NF-kB. The company plans to proceed to Phase 2 development in 1H 2015.
• Among the benefits of Orphan Drug designation is a seven-year period of market exclusivity if approved.
• DMD-related tickers: (SRPT +7.6%)(RNA +63.3%)(BMRN +1.7%)(PTCT +3.4%)(MRNA -3.3%)(ROSG-OLD +0.8%)